Goossens–Devriendt syndrome (also called brain malformation–congenital heart disease–postaxial polydactyly syndrome) is a very rare genetic condition first described in a few newborns who had four main findings together: poor growth before birth, a brain malformation, a congenital heart defect, and extra fingers or toes on the little-finger side (postaxial polydactyly). Doctors also noticed other problems can appear, such as feeding issues, low muscle tone, seizures in some children, and delayed development. Because it is so rare, doctors still do not know the exact gene for every child, and care focuses on finding problems early and treating each one carefully. e2g-portal.stanford.edu+3orpha.net+3rarediseases.info.nih.gov+3

Goossens-Devriendt syndrome is an ultra-rare condition present from birth that combines (1) brain malformations (especially changes around the pituitary gland and the cerebellar vermis), (2) congenital heart disease, and (3) postaxial polydactyly (an extra little finger or toe on the outside of the hand/foot). Many babies are small before birth, may have distinctive facial features and hair changes, and later show slow growth and significant developmental delay. Because so few people have been described, we still have limited data. rarediseases.info.nih.gov+2orpha.net+2 The syndrome is named after clinicians who reported a sib-pair (two affected sisters) with the same striking triad—heart defect, postaxial polydactyly, and pituitary/brain anomalies—along with characteristic facial features and hair findings, leading them to propose a “new syndrome.” Lippincott Journals

---

Other names

• Brain malformation–congenital heart disease–postaxial polydactyly syndrome (a descriptive name used in medical databases). rarediseases.info.nih.gov+1

• Abbreviated in some resources as BM-CHD-PAP (descriptive shorthand sometimes used in catalogs based on the same triad). e2g-portal.stanford.edu

---

Types

Because so few patients are known, there is no official sub-typing. Clinicians sometimes describe patterns that can help with care planning:

1. With major heart disease (e.g., complex structural heart defect) versus with minor/no heart disease;

2. With pituitary-hormone dysfunction (due to neuropituitary/adenopituitary anomalies) versus without obvious hormonal deficiency;

3. With renal anomalies versus without renal anomalies;

4. With marked hair/temporal balding versus without hair changes.
   These practical groupings reflect the features repeatedly noted in published descriptions and databases but are not formal genetic “types.” rarediseases.info.nih.gov

---

Causes

Key point: The root cause is not yet pinned to a specific gene. Below are twenty plausible, evidence-informed mechanisms or contributors clinicians consider when evaluating a child with this phenotype. They are hypotheses based on what we know about similar developmental disorders and the features repeatedly reported in this syndrome (brain/pituitary malformations, heart defects, limb patterning errors). I’ll note clearly when an item is general (not proven for this exact syndrome).

1. Undiscovered single-gene variant affecting early brain, heart, limb, and pituitary development (suspected from familial cases; gene unknown). Lippincott Journals+1

2. Errors in forebrain–midline and pituitary development pathways (consistent with ectopic neuropituitary, hypoplastic adenopituitary). General mechanism inferred from the syndrome’s pituitary findings. rarediseases.info.nih.gov

3. Disruption of limb patterning signals that guide postaxial digit formation (general developmental biology principle; aligns with postaxial polydactyly). rarediseases.info.nih.gov

4. Perturbation of cardiac morphogenesis pathways, leading to congenital heart disease (general mechanism consistent with the phenotype). rarediseases.info.nih.gov

5. Embryonic ciliopathy-like mechanisms (cilia are crucial for brain/limb/heart patterning; speculative but biologically plausible in triad syndromes). ScienceDirect

6. Neural crest–related disturbances (neural crest contributes to parts of the heart and craniofacial structures; mechanism extrapolated from neurocristopathy literature). MDPI

7. Regulatory (non-coding) variant altering expression timing of developmental genes (general mechanism increasingly recognized in rare syndromes). ScienceDirect

8. Copy-number variant (microdeletion/duplication) that has not yet been recurrently identified in this phenotype (general cause of syndromic developmental disorders). ScienceDirect

9. Epigenetic dysregulation during early embryogenesis (general rare-disease mechanism; explanatory when sequencing is unrevealing). ResearchGate

10. Multigenic/oligogenic interaction (two or more subtle variants together produce the full triad; general concept in rare dysmorphology). ResearchGate

11. De novo variant in a critical developmental gene (fits sporadic presentation in ultra-rare syndromes). ScienceDirect

12. Inherited recessive variant (fits the two-sisters report; still unproven without gene discovery). Lippincott Journals

13. Mosaicism in the child (mutations present in some tissues but not others; general rare-disease mechanism). ResearchGate

14. Maternal diabetes/teratogen exposure as co-factors for heart/limb anomalies (general risk factors; not documented as causal for this exact syndrome). BioMed Central

15. Placental insufficiency contributing to intrauterine growth restriction (IUGR) seen in this syndrome (general IUGR mechanism; syndrome specifically notes IUGR). rarediseases.info.nih.gov

16. Abnormal midline signaling gradients affecting pituitary stalk placement (inferred from ectopic neuropituitary reports). rarediseases.info.nih.gov

17. Perturbed Hedgehog/GLI-axis limb patterning (biologic plausibility for postaxial polydactyly in general, not proven here). ScienceDirect

18. Chromatin-remodeling defects (broad mechanism seen across syndromic neurodevelopmental disorders when classic testing is negative). ResearchGate

19. Unknown environmental co-exposures acting with genetic predisposition (general multifactorial model in congenital anomalies). BioMed Central

20. Currently unrecognized syndrome overlap (phenocopy of other, better-defined triad conditions; careful genomic testing helps sort this out). PubMed

---

Symptoms and signs

Reminder: Individual children vary. Not every person will have all features.

1. Before-birth growth restriction (IUGR): baby measures small on prenatal scans; frequently reported in this syndrome. rarediseases.info.nih.gov

2. Postnatal growth delay: continued slow growth after birth. rarediseases.info.nih.gov

3. Congenital heart disease: ranges from simple to complex structural problems; drives early cardiology care. rarediseases.info.nih.gov

4. Postaxial polydactyly: an extra small finger/toe on the outside edge of the hand/foot. rarediseases.info.nih.gov

5. Brain/pituitary malformations: ectopic neuropituitary, hypoplastic adenopituitary, and under-developed cerebellar vermis. rarediseases.info.nih.gov

6. Possible hormone problems (from pituitary anomalies): low growth hormone or other pituitary hormone deficiencies; degree varies. rarediseases.info.nih.gov

7. Developmental delay and learning difficulties: often severe in reported cases. rarediseases.info.nih.gov

8. Distinctive facial features: hypoplastic nasal bridge, anteverted nostrils, dysplastic ears, long/smooth philtrum, narrow upper lip, prominent/asymmetric lower lip. rarediseases.info.nih.gov

9. Hair anomalies with temporal balding: hair changes described as part of the phenotype. rarediseases.info.nih.gov

10. Feeding difficulties in infancy: common in multi-system syndromes with hypotonia/developmental delay. (General but consistent with overall picture.) rarediseases.info.nih.gov

11. Low muscle tone (hypotonia): contributes to delayed motor milestones. (General in neurodevelopmental syndromes; compatible with delays reported.) rarediseases.info.nih.gov

12. Seizures (possible): not universal, but may occur in some children with brain malformations. (General to malformation syndromes.) rarediseases.info.nih.gov

13. Breathing or feeding coordination issues in newborn period: due to hypotonia and cranial features. (General but clinically relevant.) rarediseases.info.nih.gov

14. Kidney/urinary tract anomalies: included among the multi-organ malformations reported. rarediseases.info.nih.gov

15. Eye/vision concerns (possible): may stem from brain development differences; requires targeted screening. (General to brain malformation syndromes.) rarediseases.info.nih.gov

---

Diagnostic tests

A) Physical examination

1. Detailed newborn/child exam: looks for extra digits, facial features, hair pattern, growth measures (length, weight, head size). This first step guides all other testing. rarediseases.info.nih.gov

2. Cardiac exam: listens for murmurs and checks oxygenation and perfusion; abnormal findings push for heart imaging. rarediseases.info.nih.gov

3. Endocrine screening in clinic: looks for signs of low pituitary hormones (poor growth, low blood sugar, low energy). rarediseases.info.nih.gov

4. Neurologic/developmental assessment: checks tone, reflexes, milestones, and behavior to plan therapies. rarediseases.info.nih.gov

5. Dysmorphology consult: a clinical geneticist compares the child’s pattern to known syndromes and decides which genetic tests are most informative. orpha.net

B) Manual tests / bedside procedures

6. Hand/foot evaluation and functional check: counts and tests active motion/sensation of extra digits to plan possible surgical care. rarediseases.info.nih.gov

7. Growth charting over time: repeated measurements help reveal growth-hormone or thyroid issues linked to pituitary anomalies. rarediseases.info.nih.gov

8. Feeding assessment (swallow study referral if needed): bedside feeding observation may trigger instrumental swallow studies. rarediseases.info.nih.gov

9. Developmental screening tools (e.g., Bayley/Denver by therapists): guide early intervention plans. (General standard of care for developmental delay.) rarediseases.info.nih.gov

10. Vision and hearing screens: simple bedside/clinic checks that may lead to formal ophthalmology/audiology testing. (General in malformation syndromes.) rarediseases.info.nih.gov

C) Laboratory and pathology tests

11. Baseline pituitary hormone panel: growth hormone axis, ACTH/cortisol, TSH/thyroid hormones, prolactin, LH/FSH—because pituitary malformations are part of the syndrome. rarediseases.info.nih.gov

12. Blood glucose and electrolytes: hypoglycemia or sodium problems can point to hormone deficiencies. (General endocrine practice.) rarediseases.info.nih.gov

13. Genetic testing—chromosomal microarray: looks for deletions/duplications (copy-number changes) that can explain syndromic presentations when a specific gene is unknown. ScienceDirect

14. Genetic testing—exome/genome sequencing (trio if possible): searches for previously unknown gene variants that might underlie the triad. (Standard approach in undiagnosed rare syndromes.) ScienceDirect

15. Targeted endocrine stimulation tests (as directed): dynamic tests (e.g., GH stimulation, ACTH stimulation) to confirm pituitary function problems. (General endocrine evaluation for suspected hypopituitarism.) rarediseases.info.nih.gov

D) Electrodiagnostic tests

16. Electroencephalogram (EEG): used if seizures are suspected due to brain malformations or unexplained spells. (General in malformation syndromes.) rarediseases.info.nih.gov

17. Electrocardiogram (ECG): basic heart rhythm assessment alongside imaging when heart disease is present. (General cardiology care.) rarediseases.info.nih.gov

E) Imaging tests

18. Brain MRI with pituitary protocol: evaluates ectopic neuropituitary, size of the adenopituitary, and cerebellar vermis development—core to this diagnosis. rarediseases.info.nih.gov

19. Echocardiogram: ultrasound of the heart to define the exact congenital defect and plan treatment. rarediseases.info.nih.gov

20. Renal ultrasound: screens for kidney/urinary anomalies described in the syndrome. rarediseases.info.nih.gov

21. Skeletal X-rays of hands/feet: document postaxial polydactyly and guide orthopedic/hand surgery. rarediseases.info.nih.gov

22. Spine X-ray or MRI (as indicated): baseline assessment in children with significant hypotonia/developmental delay. (General supportive imaging.) rarediseases.info.nih.gov

23. Craniofacial/airway imaging (CT only if necessary): evaluates structural contributors to feeding/breathing issues. (General multidisciplinary care.) rarediseases.info.nih.gov

24. Abdominal ultrasound: broader screening for associated malformations when clinically indicated. rarediseases.info.nih.gov

25. Ophthalmologic imaging (as needed): OCT or retinal photos if eye involvement is suspected. (General to malformation syndromes.) rarediseases.info.nih.gov

Non-pharmacological treatments (therapies & other supports)

1) Coordinated care plan (care navigation).
A written plan pulls together cardiology, neurology, genetics, therapy, nutrition, and primary care. It lists diagnoses, current meds, emergency steps, and follow-up timing. This improves safety, lowers missed appointments, and ensures every specialist knows what others are doing. Families can keep a one-page summary for ER visits. This is standard practice in complex rare diseases and aligns with rare-disease program guidance to centralize information and advocate for timely reviews. rarediseases.info.nih.gov

Purpose: organize safe, continuous care.
Mechanism: reduces information gaps and delays by giving all teams the same plan. rarediseases.info.nih.gov

2) Early intervention developmental therapy.
Start therapy as soon as a delay is suspected. Services often include family-centered coaching at home to build movement, play, communication, and self-care skills. The earlier the brain gets practice, the better the progress, even when underlying syndromes are present. Many rare-disease programs and developmental resources recommend referral at diagnosis rather than waiting for delays to widen. rarediseases.info.nih.gov

Purpose: improve motor, language, social, and self-help skills.
Mechanism: high-frequency, play-based repetitions strengthen neural pathways for learning. rarediseases.info.nih.gov

3) Physical therapy (PT).
PT targets low muscle tone, balance trouble, and delayed milestones. Sessions use position changes, supported standing, gait practice, and home exercises. For children with brain differences, PT can also train safe transfers and fall prevention. Regular reassessment tracks gains and guides adaptive devices if needed. rarediseases.info.nih.gov

Purpose: build strength, balance, and mobility.
Mechanism: graded, repetitive motor practice reshapes motor circuits and improves endurance. rarediseases.info.nih.gov

4) Occupational therapy (OT).
OT helps with fine-motor skills (grasp, release), self-care (feeding, dressing), and sensory processing. When extra digits were surgically removed, OT supports hand use and splint care. Evidence from developmental disability frameworks supports task-specific, goal-focused OT to improve daily participation. rarediseases.info.nih.gov

Purpose: improve daily living skills and hand function.
Mechanism: task-oriented practice strengthens sensorimotor integration. rarediseases.info.nih.gov

5) Speech-language therapy (SLT).
SLT works on early communication, feeding safety, and later speech or alternative communication. If speech is delayed, therapists introduce augmentative and alternative communication (AAC) (pictures, tablets) early so language growth does not wait for speech. This approach is standard across neurodevelopmental syndromes. rarediseases.info.nih.gov

Purpose: safe feeding and effective communication.
Mechanism: direct oral-motor training and language scaffolding/AAC build pathways for expression and understanding. rarediseases.info.nih.gov

6) Cardiac monitoring and activity guidance.
Children with congenital heart disease need scheduled cardiology checks, echocardiograms, and rhythm review, with exercise advice tailored to the defect and surgical repairs. Clear warning signs (cyanosis, fast breathing, poor feeding) are taught to families. Rare-disease guidance highlights routine surveillance for organ-system complications. orpha.net

Purpose: detect heart complications early and guide safe activity.
Mechanism: periodic imaging and clinical review catch changes before symptoms worsen. orpha.net

7) Seizure first-aid and safety plan.
If seizures occur, families learn positioning, timing, rescue steps, and when to call emergency services. Schools and caregivers should keep a copy. This is standard epilepsy safety education applied whenever a syndrome has seizure risk. rarediseases.info.nih.gov

Purpose: reduce injury and treatment delays during a seizure.
Mechanism: trained responses and ready equipment shorten time to help. rarediseases.info.nih.gov

8) Feeding, swallowing, and nutrition support.
Feeding teams assess for reflux, choking, and slow weight gain. Plans may include thickened feeds, upright positioning, specific nipples, calorie-dense formulas, and, if needed, temporary tube feeding. This follows pediatric feeding-disorder care models widely used in rare genetic conditions. rarediseases.info.nih.gov

Purpose: safe swallowing and steady growth.
Mechanism: texture, posture, and pacing changes lower aspiration risk and improve caloric intake. rarediseases.info.nih.gov

9) Orthotics and adaptive equipment.
Ank­le-foot orthoses, standers, walkers, or customized seating can improve stability and participation. After polydactyly surgery, hand splints may guide alignment. Adaptive tools match abilities so children can join daily activities earlier. rarediseases.info.nih.gov

Purpose: safer mobility and better function.
Mechanism: external support optimizes biomechanics and energy use. rarediseases.info.nih.gov

10) Vision and hearing services.
Formal eye and hearing tests are important in any syndrome with brain and craniofacial differences. Early fitting of glasses or hearing supports helps language and learning. Rare-disease programs recommend proactive sensory screening. rarediseases.info.nih.gov

Purpose: detect and treat sensory loss early.
Mechanism: correcting input (sight/sound) boosts brain development and therapy success. rarediseases.info.nih.gov

11) Individualized education plan (IEP).
Schools provide accommodations, therapies, and goals. The IEP ensures speech, OT, PT, assistive tech, and health plans are in place. This is a key pathway for access to services over years. rarediseases.info.nih.gov

Purpose: guarantee needed school supports.
Mechanism: legally binding plan aligns teaching to the child’s needs. rarediseases.info.nih.gov

12) Sleep hygiene program.
Consistent bedtime routines, light control, and behavioral strategies reduce night wakings seen in many neurodevelopmental syndromes. Structured sleep plans are first-line before medication. ERN ITHACA

Purpose: better sleep for child and family.
Mechanism: behavior and environment changes stabilize circadian rhythm. ERN ITHACA

13) Respiratory therapy and airway clearance (when indicated).
If low tone, reflux, or heart disease leads to lung infections, airway-clearance teaching and breathing exercises can help. Early action plans reduce hospital visits. rarediseases.info.nih.gov

Purpose: keep lungs clear and reduce infections.
Mechanism: scheduled clearance and breathing practice improve ventilation and mucus removal. rarediseases.info.nih.gov

14) Gastroesophageal reflux strategies.
Upright feeds, smaller frequent meals, and safe sleep positions reduce reflux symptoms and aspiration risk; these are standard conservative measures before medicines. rarediseases.info.nih.gov

Purpose: lessen spit-ups, pain, and aspiration risk.
Mechanism: gravity and pacing minimize back-flow into the esophagus. rarediseases.info.nih.gov

15) Constipation program.
Routine fluids, fiber planning, scheduled toilet sits, and activity help prevent constipation common in low-tone children. Non-drug steps are first line in pediatric guidelines. rarediseases.info.nih.gov

Purpose: comfortable, regular stools.
Mechanism: diet, hydration, and routine stimulate bowel motility. rarediseases.info.nih.gov

16) Genetic counseling and family planning.
Counselors explain what is known, discuss testing options, recurrence risk (often uncertain), and connect families to registries. This is a core service in any rare condition. rarediseases.info.nih.gov

Purpose: informed decisions and support.
Mechanism: education plus coordinated testing for affected child and, if advised, parents/siblings. rarediseases.info.nih.gov

17) Psychosocial and parent support.
Caregiver stress is common. Social work, counseling, and rare-disease networks provide coping skills and resources for transport, equipment, and respite care. rarediseases.info.nih.gov

Purpose: protect caregiver health and resilience.
Mechanism: stress-management and resource navigation reduce burnout and improve adherence. rarediseases.info.nih.gov

18) Safety planning (home & school).
Plans cover seizure safety, feeding plans, emergency meds list, and allergy alerts. Copies stay with caregivers and school nurses. This is standard risk-reduction across complex conditions. rarediseases.info.nih.gov

Purpose: reduce preventable harm.
Mechanism: written steps and trained responders shorten response times. rarediseases.info.nih.gov

19) Immunization on schedule and infection prevention.
Routine vaccines lower risks from respiratory and other infections that can hit heart- or neuro-fragile children hard. Pediatric rare-disease guidance encourages strict adherence unless a specialist says otherwise. rarediseases.info.nih.gov

Purpose: prevent avoidable infections.
Mechanism: active immunity and community protection reduce severe illness. rarediseases.info.nih.gov

20) Registry enrollment and natural-history follow-up (if available).
Joining registries helps researchers learn the cause and best treatments, and may give families chances to join studies as they open. Rare-disease resources encourage participation to grow knowledge. rarediseases.info.nih.gov

---

Drug treatments

Important: There is no FDA-approved “disease-modifying” drug for Goossens–Devriendt syndrome. Medicines below are commonly used to treat individual problems (e.g., seizures, reflux, heart failure). Doses must be individualized by the child’s clinicians.

1) Levetiracetam (Keppra®) – anti-seizure.
Class: Antiepileptic. Typical pediatric dosing: often ~10–20 mg/kg twice daily to start, titrated by response (clinician sets exact plan). Purpose: reduce focal or generalized seizures if present. Mechanism: binds SV2A synaptic vesicle protein to reduce abnormal neuronal firing. Timing: given twice daily; steady state in a few days. Side effects: sleepiness, irritability/behavior changes; rare hypersensitivity. Evidence source: FDA label describes indications, cautions for behavioral effects, and dosing forms for pediatrics. FDA Access Data+1

2) Valproate (Depakote®/divalproex) – anti-seizure.
Class: Broad-spectrum antiepileptic. Dose: individualized; often weight-based with serum-level monitoring. Purpose: control generalized or mixed seizure types when appropriate. Mechanism: increases GABA and modulates sodium/calcium channels. Timing: divided daily; titrate slowly. Side effects: liver toxicity risk, pancreatitis, teratogenicity; tremor, weight gain. Note: strict pregnancy precautions for adolescents. Evidence source: FDA labeling includes indications and boxed warnings. FDA Access Data+1

3) Lamotrigine (Lamictal®) – anti-seizure.
Class: Antiepileptic (Na-channel modulator). Dose: slow titration to reduce rash risk; pediatric weight-based schedules exist. Purpose: focal and generalized seizures; mood stabilizing effects sometimes help irritability. Mechanism: stabilizes neuronal membranes and glutamate release. Side effects: serious skin rash (SJS/TEN) risk with rapid titration or valproate co-use, dizziness. Evidence source: FDA boxed warning and pediatric forms described. FDA Access Data+1

4) Furosemide (Lasix®) – diuretic for heart failure physiology.
Class: Loop diuretic. Dose: pediatric mg/kg dosing determined by cardiology. Purpose: control fluid overload with some congenital heart defects. Mechanism: blocks Na-K-2Cl transporter in loop of Henle to increase urine output. Side effects: dehydration, low potassium, ototoxicity risk with high IV doses. Evidence source: FDA labeling and warnings. FDA Access Data+1

5) Omeprazole (Prilosec®) – reflux management.
Class: Proton-pump inhibitor. Dose: weight- and age-based; pediatric GERD labeling describes short-term use including infants for erosive esophagitis under specialist guidance. Purpose: reduce painful acid reflux and esophagitis that can worsen feeding. Mechanism: blocks gastric H+/K+ ATPase to cut acid production. Side effects: headache, diarrhea; long-term use requires caution. Evidence source: FDA labels (adult and pediatric). FDA Access Data+1

6) Polyethylene glycol 3350 (PEG 3350) – constipation relief.
Class: Osmotic laxative. Dose: clinician-directed; commonly daily titration to soft stool. Purpose: treat chronic constipation common with low tone. Mechanism: holds water in stool to soften and increase frequency. Side effects: bloating; rare electrolyte issues if misused. Evidence source: FDA monograph/labels. FDA Access Data+1

7) Baclofen (oral) – spasticity or severe tone patterns.
Class: GABA-B agonist muscle relaxant. Dose: low start with slow increases; special pediatric formulations exist. Purpose: reduce spasticity patterns that interfere with care or comfort. Mechanism: presynaptic inhibition reduces excitatory neurotransmission in spinal cord. Side effects: sleepiness, low tone, withdrawal if stopped abruptly. Evidence source: FDA labels (OZOBAX®, LYVISPAH®). FDA Access Data+1

8) Albuterol – reactive airway symptoms.
Class: Short-acting beta-2 agonist. Dose: inhaled; age-specific directions on label. Purpose: treat wheeze that may complicate feeding or respiratory infections. Mechanism: bronchodilation via airway smooth-muscle relaxation. Side effects: tremor, fast heart rate. Evidence source: FDA labels (HFA inhaler and nebulizer solution). FDA Access Data+1

9) Clonazepam – rescue or adjunct for seizures (specialist use).
Class: Benzodiazepine anticonvulsant. Dose: individualized and closely monitored. Purpose: adjunct control of certain seizure types or as interim therapy. Mechanism: enhances GABA-A receptor activity. Side effects: sedation, dependence risk with long use. Evidence source: FDA labeling. FDA Access Data

10) Multivitamin with iron (when deficient) – clinician-directed.
Class: Nutrient replacement (OTC/Rx forms). Dose: based on age and lab values. Purpose: correct iron deficiency that worsens fatigue and development. Mechanism: supports hemoglobin and neurodevelopmental processes. Safety: iron can be toxic if overdosed; use only with medical guidance. Evidence source: pediatric practice standards; specific products have FDA labeling as dietary supplements are regulated differently. rarediseases.info.nih.gov

11) Vitamin D (therapeutic dosing if low).
Class: Nutrient replacement. Dose: lab-guided repletion then maintenance. Purpose: bone health, muscle function. Mechanism: aids calcium absorption and bone mineralization. Safety: avoid over-supplementation. Evidence source: pediatric endocrine practice norms for deficiency. rarediseases.info.nih.gov

12) Ondansetron – vomiting with acute illness (clinician-directed).
Class: 5-HT3 antagonist antiemetic. Dose: weight-based. Purpose: reduce vomiting that worsens dehydration. Mechanism: blocks serotonin receptors in gut/brain. Side effects: constipation, headache, rare QT issues. Evidence source: FDA label supports pediatric use in certain settings. rarediseases.info.nih.gov

13) Propranolol or other agents for troublesome arrhythmia (cardiology-directed).
Class: Beta-blocker. Dose: titrated by cardiology. Purpose: manage rhythm abnormalities tied to congenital heart disease. Mechanism: slows AV conduction and reduces adrenergic drive. Side effects: bradycardia, low blood pressure, hypoglycemia risk in infants. Evidence source: cardiology standards; FDA labels detail indications/risks. orpha.net

14) ACE inhibitor (e.g., enalapril) for heart failure physiology (cardiology-directed).
Class: RAAS blocker. Dose: carefully titrated. Purpose: reduce afterload and support ventricular function. Mechanism: blocks angiotensin-converting enzyme to dilate vessels. Side effects: cough, kidney effects, high potassium. Evidence source: pediatric heart-failure practice; FDA label exists for enalapril. orpha.net

15) Thickening agents for dysphagia (medical food).
Class: Food/medical food, not a drug; listed here because it’s often “prescribed” by clinicians. Purpose: reduce aspiration with thin liquids. Mechanism: increases viscosity to slow flow and aid airway protection. Safety: use products appropriate for infants/children per speech-therapy guidance. rarediseases.info.nih.gov

16) Topical skin care for drooling/dermatitis.
Class: barrier ointments (zinc oxide, etc.). Purpose: protect skin around mouth and neck. Mechanism: moisture barrier to prevent breakdown. Evidence: standard pediatric dermatology practice. rarediseases.info.nih.gov

17) Sodium chloride nebulization (when prescribed) for thick secretions.
Class: Airway hydrating solution. Purpose: loosen mucus during infections. Mechanism: draws water into airway surface liquid. Caution: use only if a clinician advises. rarediseases.info.nih.gov

18) Prophylactic antibiotics around cardiac surgery (peri-operative protocols).
Class: Antibacterials as per hospital pathways. Purpose: reduce surgical site infection. Mechanism: bactericidal coverage during exposure. Evidence: surgical standards; individualized by cardiothoracic team. orpha.net

19) Pain control after surgery (acetaminophen/ibuprofen, clinician guidance).
Class: Analgesics. Purpose: comfort and faster recovery. Mechanism: central COX inhibition (acetaminophen different), peripheral COX for ibuprofen. Caution: dosing by weight; avoid duplication. rarediseases.info.nih.gov

20) Emergency seizure rescue medicines (e.g., intranasal benzodiazepine) – as prescribed.
Class: Benzodiazepines. Purpose: stop prolonged seizures outside hospital. Mechanism: enhances GABA to abort seizure. Caution: strict caregiver training. Evidence: FDA-labeled products for seizure clusters exist; prescribers select age-appropriate options. rarediseases.info.nih.gov

---

Dietary molecular supplements

1) Omega-3 (EPA/DHA).
Description & function: Omega-3 fats are building blocks for brain cell membranes and help regulate inflammation. In neurodevelopmental disorders, they are sometimes considered for attention, behavior, or general brain health, although benefits vary. In heart disease, omega-3s may modestly support triglyceride control. For a child with feeding challenges, liquid or micro-encapsulated forms can be easier. Dosage: pediatric dosing is weight-based; many clinicians start low and monitor for GI upset. Mechanism: integrates into neuronal membranes (fluidity), modulates eicosanoid pathways, and may affect synaptic signaling. Caution: fish-oil can thin blood slightly; stop before surgery and discuss allergies. Evidence is mixed; use as an adjunct, not a cure. rarediseases.info.nih.gov

2) Vitamin D3.
Description: Supports bones, muscles, and immune function—important if mobility is limited or nutrition is marginal. Deficiency is common in children who spend less time outdoors or have feeding issues. Dosage: only after measuring blood levels; doctors use a short repletion phase then maintenance. Mechanism: increases calcium absorption and helps bone mineralization; also modulates immune signaling. Caution: too much can harm; never mega-dose without labs. rarediseases.info.nih.gov

3) Iron (if iron-deficient).
Description: Iron supports oxygen delivery and brain development. When labs show deficiency, oral iron (with vitamin C foods) is used to restore stores; this can improve energy and attention. Dosage: weight-based elemental iron; exact plan from the clinician. Mechanism: hemoglobin synthesis and myelination support. Caution: constipation and dark stools; keep out of children’s reach due to overdose risk. rarediseases.info.nih.gov

4) Magnesium.
Description: Magnesium participates in neuromuscular function and may ease constipation when used as a gentle osmotic (in specific forms). Dosage: clinician-directed; excess causes diarrhea. Mechanism: cofactor in hundreds of enzymes, affects NMDA receptor activity and smooth-muscle relaxation. Caution: avoid in kidney disease unless supervised. rarediseases.info.nih.gov

5) Coenzyme Q10.
Description: CoQ10 helps mitochondria make energy (ATP). Some clinicians try it when fatigue or exercise intolerance complicates care, though evidence is mixed. Dosage: mg/kg/day divided; oil-based forms absorb better. Mechanism: electron transport chain cofactor and antioxidant. Caution: interacts with warfarin; discuss before starting. rarediseases.info.nih.gov

6) L-carnitine.
Description: Carnitine shuttles fatty acids into mitochondria for energy. It is sometimes used for feeding intolerance or as an adjunct in certain antiepileptic regimens (e.g., valproate-related carnitine depletion), but only when a clinician sees a reason. Dosage: mg/kg/day divided. Mechanism: facilitates β-oxidation. Caution: can cause GI upset or “fishy” odor. rarediseases.info.nih.gov

7) Probiotics.
Description: In children with reflux, constipation, or frequent antibiotics, a carefully chosen probiotic may help stool regularity and reduce some GI symptoms. Dosage: product-specific CFU; start low. Mechanism: microbiome modulation, SCFA production, barrier effects. Caution: avoid in severely immunocompromised patients. rarediseases.info.nih.gov

8) Folate (or methyl-folate if advised).
Description: Needed for cell division and neural development; used only when deficiency or specific metabolic concerns are found. Dosage: age-appropriate RDA replacement unless specialist prescribes more. Mechanism: one-carbon metabolism and DNA methylation. Caution: can mask B12 deficiency—labs first. rarediseases.info.nih.gov

9) Zinc.
Description: Supports immunity, wound healing, taste/smell, and growth. In picky eaters or those with chronic GI losses, zinc repletion can help. Dosage: short courses per clinician; high doses cause copper deficiency. Mechanism: cofactor for >300 enzymes; impacts mucosal immunity. rarediseases.info.nih.gov

10) Medium-chain triglycerides (MCT oil).
Description: Easier-to-absorb fats that can raise calories in small volumes—useful in poor weight gain. Dosage: introduced slowly; mixed into foods or formula. Mechanism: rapid liver metabolism for energy without complex digestion. Caution: can cause diarrhea if too fast or too much. rarediseases.info.nih.gov

---

Immunity-booster / regenerative / stem-cell drugs

Key message: There are no FDA-approved stem-cell or gene-therapy drugs for Goossens–Devriendt syndrome. Using unproven “stem-cell” or “regenerative” injections outside regulated trials can be unsafe. Below are safer, evidence-aligned alternatives that strengthen protection and recovery where appropriate.

1) Routine childhood vaccines (program-based, not a single drug).
100-word overview: Staying up to date with vaccines gives the strongest safe “immunity boost,” especially for children with heart or neurologic conditions who can get sicker from common infections. Vaccines prime the immune system to recognize germs fast. Dosage: per national schedule. Function/mechanism: active immunization induces antigen-specific memory B- and T-cell responses to prevent severe disease. Discuss any surgery timing with your team. rarediseases.info.nih.gov

2) Palivizumab (Synagis®) for selected high-risk infants (specialist decision).
100-word overview: A monoclonal antibody given during RSV season to some infants with significant heart or lung disease lowers hospitalization risk. Dose: monthly injections in season, weight-based. Function/mechanism: passive immunity—antibody binds RSV F protein to neutralize virus. Note: not for all children; cardiology/pulmonology decides. FDA-approved for RSV prophylaxis in defined groups. rarediseases.info.nih.gov

3) Seasonal influenza vaccination (annual).
100-word overview: Flu can severely affect children with heart or neurologic issues. Yearly flu shots reduce serious illness and hospitalizations. Dose: annual per age. Function/mechanism: active immunity to current strains. Note: household members should be vaccinated to shield the child. rarediseases.info.nih.gov

4) Nutritional immuno-support (vitamin D, zinc if low) under labs.
100-word overview: Correcting documented deficiencies (not mega-dosing) supports immune function and healing. Dose: lab-guided. Mechanism: micronutrients are co-factors for immune cells and barriers. Note: excess can harm; use only as prescribed. rarediseases.info.nih.gov

5) IVIG (intravenous immunoglobulin) only if proven immunodeficiency.
100-word overview: If testing shows antibody deficiency, immunologists may consider IVIG to prevent recurrent infections. Dose: weight-based every 3–4 weeks. Mechanism: provides pooled IgG antibodies for passive protection. Note: this is not routine in Goossens–Devriendt and is used only when criteria are met. rarediseases.info.nih.gov

6) Research participation (gene discovery/natural-history) rather than unregulated stem-cell clinics.
100-word overview: The most meaningful “regenerative” step today is to enroll in legitimate studies/registries so scientists can define the gene and pathways and someday design targeted therapies. Function/mechanism: builds the evidence base for future treatments. Safety: protects families from unproven interventions. rarediseases.info.nih.gov

---

Surgeries

1) Congenital heart defect repair.
Procedure: Depending on the defect (e.g., septal defect, outflow tract issue), cardiothoracic surgeons repair or palliate the lesion in one or staged operations. Why: improve oxygen delivery, prevent heart failure or pulmonary hypertension, and support normal growth. Follow-up: lifelong cardiology care. orpha.net

2) Postaxial polydactyly excision/reconstruction.
Procedure: Remove extra finger or toe and reconstruct soft tissues; timing depends on digit type and function. Why: improve function, shoe fit, and hand use; reduce skin breakdown. Therapy: OT splinting and exercises afterward. orpha.net

3) Neurosurgical shunt or endoscopic third ventriculostomy (if hydrocephalus present).
Procedure: CSF shunt placement or ETV to relieve pressure from obstructed CSF flow when associated brain malformations cause hydrocephalus. Why: prevent brain injury from high pressure and improve feeding/alertness. OUP Academic

4) Gastrostomy tube (with or without fundoplication).
Procedure: Place a feeding tube into the stomach; sometimes add anti-reflux surgery if severe aspiration. Why: ensure safe nutrition, medications, and growth when oral feeding is unsafe or insufficient. Team: GI, surgery, nutrition, SLT. rarediseases.info.nih.gov

5) Orthopedic procedures (select cases).
Procedure: Tendon releases, foot corrections, or hip stabilization if tone patterns or limb alignment limit function. Why: reduce pain, improve positioning, and aid mobility and care. Rehab: PT is essential post-op. rarediseases.info.nih.gov

---

Preventions

1. Keep all scheduled heart and neuro follow-ups and imaging. Early detection prevents crises. orpha.net

2. Follow immunization schedules and seasonal prophylaxis if eligible. rarediseases.info.nih.gov

3. Use seizure safety plans and rescue meds exactly as taught. rarediseases.info.nih.gov

4. Build daily bowel and reflux routines to avoid complications. rarediseases.info.nih.gov

5. Practice strict hand hygiene and sick-day plans, especially in RSV/flu seasons. rarediseases.info.nih.gov

6. Maintain therapy home-program routines; small daily practice prevents regressions. rarediseases.info.nih.gov

7. Keep a one-page emergency care summary in bags, school, and car. rarediseases.info.nih.gov

8. Use adaptive equipment correctly; check fit as the child grows. rarediseases.info.nih.gov

9. Provide safe sleep and positioning to reduce reflux aspiration. rarediseases.info.nih.gov

10. Enroll with rare-disease resources/registries to learn updates and studies. rarediseases.info.nih.gov

---

When to see doctors (or urgent care)

Seek urgent care for blue lips/skin, fast or difficult breathing, poor feeding with sweating, seizures lasting >5 minutes or repeating without full recovery, severe dehydration, new weakness, or high fevers not responding to medication. Schedule routine visits for growth checks, therapy reviews, immunizations, and any new concerns about development, sleep, feeding, or behavior. Rare-disease resources emphasize early evaluation because small changes can signal evolving heart or neuro issues. orpha.net+1

---

Foods to eat and to avoid

What to eat (examples):

1. Energy-dense foods (nut butters, avocado) to help growth when volumes are small.

2. High-quality proteins (eggs, fish, lentils) for muscle and healing.

3. Fruits/vegetables for fiber and micronutrients (peeled or cooked if texture helps).

4. Whole-grain options for fiber if tolerated.

5. Yogurt with live cultures (if dairy-tolerant) for gut health.

6. Fortified cereals or milks to support iron and vitamin D intake.

7. Oils like olive or canola to raise calories without large volumes.

8. Smooth textures and thickened liquids if advised by SLT.

9. Adequate fluids spaced through the day to prevent constipation.

10. Specialized formulas or add-ins (MCT, modulars) when prescribed. rarediseases.info.nih.gov

What to avoid or limit (as advised):

1. Very thin liquids if there is aspiration risk—use thickening if prescribed.

2. Hard, crumbly, or mixed-texture foods that are choking hazards.

3. Excess juice/sugary drinks that worsen reflux or diarrhea.

4. Caffeine in older kids—can worsen reflux and sleep.

5. Ultra-processed snacks that displace nutrient-dense foods.

6. High-sodium foods if heart issues require restriction.

7. Large meals near bedtime (reflux risk).

8. Allergen-containing foods if a known allergy exists.

9. Unpasteurized products.

10. Mega-doses of supplements without labs or medical advice. rarediseases.info.nih.gov

---

FAQs

1) Is there a cure?
No disease-specific cure exists yet. Care focuses on early detection and treatment of each problem (heart, brain, feeding, development) to maximize function and quality of life. Research and registries may help future therapies. orpha.net+1

2) How rare is it?
Extremely rare—listed by major rare-disease references with prevalence under 1 in a million, which explains why knowledge is still limited. orpha.net

3) What causes it?
It is genetic, but the specific gene may differ and is not always found yet. Doctors use broad genetic testing (panels/exome) to search for a cause. rarediseases.info.nih.gov

4) How is it diagnosed?
By its characteristic combination—brain malformation, congenital heart defect, and postaxial polydactyly—plus growth restriction and other findings. Genetic testing supports the diagnosis. beta.monarchinitiative.org+1

5) What specialists are needed?
Usually cardiology, neurology, genetics, PT/OT/SLT, GI/nutrition, ophthalmology/audiology, and primary care. Team care is standard for rare multisystem conditions. rarediseases.info.nih.gov

6) Do children with this condition always have seizures?
No. Some do and some do not; when present, standard epilepsy medicines are used and tailored to the child. rarediseases.info.nih.gov

7) Can surgery fix everything?
Surgery can correct certain problems (heart defects, extra digits, hydrocephalus, feeding access), but therapies and medical care remain important after surgery. orpha.net+1

8) Will my child walk and talk?
Outcomes vary because brain differences and overall health differ by child. Early therapy, AAC for communication, and school supports improve function regardless of the final level achieved. rarediseases.info.nih.gov

9) Is it like Mowat–Wilson syndrome?
Some features overlap (brain, heart, development), but Goossens–Devriendt is defined by the triad including postaxial polydactyly and has its own listing in rare-disease catalogs. Genetic causes differ. BioMed Central+1

10) What about growth and feeding?
Feeding teams can improve safety and calorie intake; some children need temporary or long-term tube feeding. Growth is monitored closely. rarediseases.info.nih.gov

11) Are there clinical trials?
Because it’s very rare, trials are limited; registries and natural-history studies are most common, and families should check rare-disease portals and genetics centers. rarediseases.info.nih.gov

12) What should we bring to the ER?
A one-page summary listing diagnoses, surgeries, meds with doses, allergies, key specialist contacts, and your child’s baseline status. rarediseases.info.nih.gov

13) How can schools help?
Through an individualized education plan with therapy minutes, AAC access, health plans (seizure/feeding), and accommodations for fatigue or medical visits. rarediseases.info.nih.gov

14) Are complementary treatments okay?
Discuss each option with your team; avoid unregulated “stem-cell” clinics or mega-supplements. Choose therapies with safety data and clear goals. rarediseases.info.nih.gov

15) What’s the long-term outlook?
It depends on the heart defect type, brain involvement, and access to early therapies. Many children make gains with comprehensive support. Ongoing follow-up allows timely adjustments. orpha.net+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 02, 2025.

PDF Documents For This Disease Condition References